NCT07306624

Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer

A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination With Docetaxel in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/or Immunotherapy

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 62 (estimated)
• Sponsor: STCube, Inc. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination with Docetaxel in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/or Immunotherapy

Detailed description

This is a singble arm, open label, phase 2 study to evaluate safety and preliminary efficacy for Nelmastobart 800mg and docetaxel 75mg/m2 combination regimen for both AGA negative and positive NSCLC patients who have failed at least 1 line of treatment including platinum based chemotherapy.

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Nelmastobart and Docetaxel	Nelmastobart 800mg and Docetaxel 75mg/m2

Timeline

• Start date: 2026-01-10
• Primary completion: 2027-08-31
• Completion: 2027-08-31
• First posted: 2025-12-29
• Last updated: 2026-01-15

Locations

5 sites across 1 country: South Korea